News for Healthier Living

ASH: Monoclonal Antibody Therapy Improves Survival in Cancer-Associated Hyper-Inflammatory Disorder

Adult patients with newly diagnosed malignancy-associated hemophagocytic lymphohistiocytosis (mHLH) - a rare, aggressive hyperinflammatory condition - who were treated with the first-in-class monoclonal antibody, ELA026, experienced a 100% response rate and an improved survival rate at two months, according to researchers from The University of Texas MD Anderson Cancer Center.

December 9, 2024


December 21 2024

December 20 2024

December 19 2024

December 18 2024

December 17 2024

December 16 2024

December 15 2024

December 14 2024

December 13 2024

December 12 2024

December 11 2024

December 10 2024

December 9 2024

December 8 2024

December 7 2024